Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 23, 2026BiomedicinesOpen Access

The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMizuki ArigaTKTeiji KuzuyaHMHisanori Muto

Discussion

Loading...

Member takes

Overview

Analysis reveals liver function's role in post-progression survival in patients with advanced HCC, suggesting critical treatment implications.

Key Points

  • This research aims to identify factors influencing post-progression survival in patients with advanced hepatocellular carcinoma treated with Atz+Bev.
  • Retrospective analysis of 132 patients with HCC receiving Atz+Bev.
  • Assessment of tumor response using RECIST v1.1.
  • Evaluation of factors like Child–Pugh scores and ECOG performance status at progression.
  • Median overall survival was 21.2 months, with a median post-progression survival of 9.2 months.
  • Patients maintaining Child–Pugh A and ECOG PS 0/1 had a median PPS of 14.7 months, compared to 2.0 months otherwise.
  • Factors predicting prolonged PPS include ECOG PS 0, Child–Pugh A, no portal vein invasion, and AFP < 400 ng/mL.

Cite This Study

Ariga et al. (2026) studied this question.

synapsesocial.com/papers/69730fc4c8125b09b0d1f905https://doi.org/10.3390/biomedicines14010232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma2024 · 1 citations
  2. 2Survival outcomes in patients (pts) with Child-Pugh class B (CP-B) liver function at progression after first-line atezolizumab-bevacizumab (Atezo-Bev) for unresectable hepatocellular carcinoma (uHCC): Asia-Pacific multicenter retrospective analysis.2026
  3. 3Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B2025 · 4 citations
  4. 4Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma2026
  5. 5Disease complexity and nodule-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma2025